Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of PRN Dosing of BXCL501 Over a 12 Week Treatment Period in Subjects With Agitation Associated With Dementia Who Require at Least Moderate To Full Assistance With Activities of Daily Living

NCT05665088 is registered in ClinicalTrials.gov with BioXcel Therapeutics Inc as lead sponsor.

NCT NCT05665088
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05665088 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of PRN Dosing of BXCL501 Over a 12 Week Treatment Period in Subjects With Agitation Associated With Dementia Who Require at Least Moderate To Full Assistance With Activities of Daily Living
Lead sponsor
BioXcel Therapeutics Inc
Phase
Phase 3
Overall status
Terminated
Start date
December 5, 2022
Completion date
September 11, 2023
Enrollment
13 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

agitation, dementia